Caris Life Sciences to highlight new approaches for gynecologic cancers at SGO 2011 conference

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from the company's upcoming symposium, "Using Biomarker Expression to Guide Therapy: An Evidence-Based Approach for Gynecologic Cancers," at the Society of Gynecologic Oncologists ("SGO") 2011 Annual Meeting on Women's Cancer in Orlando, FL on March 6. The symposium features Dr. Daniel Von Hoff, distinguished professor and physician-in-chief at The Translational Genomics Research Institute and consultant to Caris Life Sciences; Mike F. Janicek, MD of Arizona Oncology; and John Geisler, MD of University of Toledo Medical Center. Symposium course director Dr. Robert Bristow, director of the division of gynecologic oncology at the University of California Irvine, will open the program by discussing the current role of personalized medicine in gynecologic oncology.

Dr. Von Hoff will summarize clinical data indicating that using the Caris Target Now™ evidence-based molecular profiling service to guide cancer therapy selection in advanced cancers can favorably impact the natural course of the disease. The esteemed panel of physicians and cancer researchers will also discuss new enhancements to the Caris Target Now service, including the addition of new biomarker assessment technologies, such as direct gene sequencing and Fluorescent In-Situ Hybridization (FISH), and a new biomarker profile designed specifically for ovarian cancer.

"Ovarian cancer is one of the most lethal gynecologic cancers in the U.S., resulting in nearly 15,000 deaths annually," Dr. Von Hoff commented. "SGO works at the forefront of managing this and related gynecologic cancers, and this symposium will enhance awareness of the clinical utility of molecular profiling for patients with advanced gynecologic malignancies."

Caris Target Now uses an evidence-based molecular profiling approach to provide treatment options for cancer patients, including women with ovarian cancer.Data has shown that although ovarian cancer patients may have progressed on prior therapies, in over 98 percent of patients, potential treatment targets can be found and targeted with available therapeutic agents that might not have been considered for these tumors.The Caris Target Now service can help physicians and their patients identify and navigate treatment options for this extremely rapid and fatal disease, often illuminating therapies that otherwise wouldn't have been considered.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blood-based biomarkers could revolutionize Alzheimer's diagnosis and treatment